Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Determination if Indirectly Reducing Circulating Insulin by Improving Insulin Sensitivity With Pioglitazone Reduces Renal Clearance of D-chiro-inositol (DCI) Increases the Circulating Concentration of DCI and Enhances Insulin-stimulated Release of the D-chiro-inositol-containing Inositolphosphoglycan (DCI-IPG) Mediator in Obese Women With PCOS

NCT00868140 is registered in ClinicalTrials.gov with Virginia Commonwealth University as lead sponsor.

NCT NCT00868140
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00868140 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Determination if Indirectly Reducing Circulating Insulin by Improving Insulin Sensitivity With Pioglitazone Reduces Renal Clearance of D-chiro-inositol (DCI) Increases the Circulating Concentration of DCI and Enhances Insulin-stimulated Release of the D-chiro-inositol-containing Inositolphosphoglycan (DCI-IPG) Mediator in Obese Women With PCOS
Lead sponsor
Virginia Commonwealth University
Phase
Not applicable
Overall status
Terminated
Start date
February 28, 2009
Completion date
August 31, 2011
Enrollment
51 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

polycystic ovary syndrome